Proteomics Reveals Age as Major Modifier of Inflammatory CSF Signatures in Multiple Sclerosis
This study unveils a unique CSF proteomic signature in MS, providing new pathophysiologic insights and identifying novel biomarker candidates and potential therapeutic targets. Our findings highlight similar immunologic mechanisms in relapsing and progressive MS and underscore aging's profound effect on the intrathecal immune response. This aligns with the observed lower efficacy of immunotherapies in the elderly, thus emphasizing the necessity for alternative therapeutic approaches in treating individuals with MS beyond the age of 50.
Authors
- Friederike Held (ORCID: https://orcid.org/0009-0008-1190-9435)
- Achim Berthele (ORCID: https://orcid.org/0000-0001-9650-6222)
- Bernhard Hemmer (ORCID: https://orcid.org/0000-0001-5985-6784)
- Verena Grummel
- Martina Flaskamp
- Christiane Gasperi (ORCID: https://orcid.org/0000-0002-0524-6005)
- Christine Makarov (ORCID: https://orcid.org/0009-0001-1711-187X)
Institutions
- Munich Cluster for Systems Neurology (DE)
Publication Details
- Journal
- Neurology Neuroimmunology & Neuroinflammation
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1212/nxi.0000000000200322
- Citations
- 11
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.67
Funders
- Sanofi
- Biogen
- Alexion Pharmaceuticals
- TG Therapeutics
- Argenx
- European Commission
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- Technische Universität München
- Hans und Klementia Langmatz Stiftung
- Sanofi Genzyme